Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Hedgehog Proteins
  • Neoplasms
  • Pyridines
  • Pyrroles
  • Signal Transduction

abstract

  • TAK-441 was generally well tolerated up to MFD of 1,600 mg/day, with preliminary antitumor activity. Further study of TAK-441 may be appropriate in populations selected for tumors with ligand-dependent or independent Hedgehog signaling.

publication date

  • March 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-14-1234

PubMed ID

  • 25501576

Additional Document Info

start page

  • 1002

end page

  • 9

volume

  • 21

number

  • 5